Owner Merck Patent GmbH

Inventors MacDonald, Glen Christopher; Bosc, Denis Georges; Cizeau, Jeannick; Carr, Francis J.; Hellendoorn, Koen; Baker, Matthew; Entwistle, Joycelyn; Glover, Nicholas Ronald

Agent Davies Collison Cave

Pub. Number AU-B-2005224942

PCT Pub. Number WO2005/090579

Priority 60/554,580 19.03.04 US; 60/630,571 26.11.04 US

Filing date 18 March 2005

Wipo publication date 29 September 2005

Acceptance publication date 11 August 2011

C07K 7/08 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

A61K 38/16 (2006.01) Medicinal preparations containing peptides - Peptides having more than 20 amino acids

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

A61P 35/00 (2006.01) Antineoplastic agents

C07K 14/415 (2006.01) Peptides having more than 20 amino acids - from plants

C07K 16/30 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/44 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material not provided for elsewhere

C07K 19/00 (2006.01) Hybrid peptides

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

C12N 15/13 (2006.01) Mutation or genetic engineering - Immunoglobulins

C12N 15/29 (2006.01) Mutation or genetic engineering - Genes encoding plant proteins, e.g. thaumatin

C12N 15/62 (2006.01) Mutation or genetic engineering - DNA sequences coding for fusion proteins

A61K 38/00 (2006.01) Medicinal preparations containing peptides